EUVIMEDEUVIMED entdecken
Crossref

Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS‐CoV‐2

Laura E Kuczynski iD, James R Shallow, Matthew P Watson, Michael L Homsy, Thomas Svab, Ashley Gruber, Richard R Rustandi, Jianfang Hu, Michael A Winters

Biotechnology Journal · 2024

DOI: 10.1002/biot.202300041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Laura E Kuczynski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Process Research & Development, MRL, Merck & Co., Inc., West Point, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ebola Vaccines, Hemorrhagic Fever, Ebola, Viral Vaccines, Vesicular Stomatitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the COVID‐19 pandemic, long development timelines typically associated with vaccines were challenged. The urgent need for a vaccine provided a strong driver to reevaluate existing vaccine development approaches. Innovative approaches to regulatory approval were realized, including the use of platform‐based technology. In collaboration with the International AIDS Vaccine Initiative, Inc. (IAVI), Merck & Co., Inc., Rahway, NJ, USA rapidly advanced an investigational SARS‐CoV‐2 vaccine based on the recombinant vesicular stomatitis virus (rVSV) platform used for the Ebola vaccine ERVEBO (rVSV∆G‐ZEBOV‐GP). An rVSV∆G‐SARS‐CoV‐2 vaccine candidate was generated using the SARS‐CoV‐2 spike protein to replace the VSV G protein. The purification process development for this vaccine candidate was detailed in this paper. Areas were highlighted where the ERVEBO platform process was successfully adopted and where additional measures were needed for the SARS‐CoV‐2 vaccine candidate. These included: (i) endonuclease addition directly into the bioreactor prior to harvest, (ii) inclusion of a core‐shell chromatography step for improved purification, and (iii) incorporation of a terminal, sterile filtration step to eliminate the need for aseptic, closed processing. High infectious virus titers were achieved in Phase 3 clinical drug substance (>10 8 PFU mL −1 ), and process consistency was demonstrated across four large scale batches that were completed in 6 months from clone selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ebola VaccinesHemorrhagic Fever, EbolaViral VaccinesVesicular StomatitisEbolavirusCOVID-19Spike Glycoprotein, CoronavirusAnimalsHumansCOVID-19 VaccinesSARS-CoV-2PandemicsVesiculovirusVesicular stomatitis Indiana virusVaccines, SyntheticAntibodies, Viral

Stichwörter der Autor:innen

COVID-19SARS-CoV-2live virus purificationsterile filtrationvesicular stomatitis virus

Substanzen

Ebola VaccinesViral Vaccinesspike protein, SARS-CoV-2COVID-19 VaccinesVaccines, SyntheticAntibodies, ViralSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Vaccine Process Research & Development, MRL, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Analytical Research & Development, MRL, Merck & Co., Inc, West Point, Pennsylvania, USA.
  • Center of Mathematical Sciences, MMD, Merck & Co., Inc., West Point, Pennsylvania, USA.

ORCID-Profile: Laura E Kuczynski

Förderung

  • U.S. Department of Health and Human Services

Zitieren

APA

Kuczynski, L. E., Shallow, J. R., Watson, M. P., Homsy, M. L., Svab, T., Gruber, A., Rustandi, R. R., Hu, J., & Winters, M. A. (2024). Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS‐CoV‐2. Biotechnology Journal. https://doi.org/10.1002/biot.202300041

Vancouver

Kuczynski LE, Shallow JR, Watson MP, Homsy ML, Svab T, Gruber A, et al. Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS‐CoV‐2. Biotechnology Journal. 2024. doi:10.1002/biot.202300041

BibTeX
@article{Kuczynski2024,
  author = {Kuczynski, Laura E and Shallow, James R and Watson, Matthew P and Homsy, Michael L and Svab, Thomas and Gruber, Ashley and Rustandi, Richard R and Hu, Jianfang and Winters, Michael A},
  title = {Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS‐CoV‐2},
  journal = {Biotechnology Journal},
  year = {2024},
  doi = {10.1002/biot.202300041}
}
Kostenlos starten →